摘要
目的:观察dl-3-正丁基苯酞(恩必普)软胶囊治疗急性脑梗死的临床疗效和安全性。方法:选择87例首次发作的急性脑梗死患者,治疗组40例、对照组47例。治疗组试验药dl-3-正丁基苯酞软胶囊,每次口服200mg,tid。对照组用药为复方丹参注射液,治疗组加用对照组用药。结果:治疗组与对照组治疗后第11和2l天的神经功能评分和生活能力评定差异有显著性。治疗组治疗前、后实验室数据无显著性差异。结论:dl-3-正丁基苯酞软胶囊治疗急性脑梗死的临床疗效明显,对肝和肾功能、血脂、血糖、EKG无明显影响,不良反应少,临床用药安全。
Aim： To assess the efficacy and safety of dl-3-butylphthalide in the treatment of acute cerebral infarction. Methods： Two groups were divided from 87 patients hospitalized in our department during the year 2004 who were first attacked by acute cerebral infarction from internal carotid artery in 72 h. Both groups were treated with Compound ＂Dan Shen＂ for 14 days as supporting therapy, while one group of 40 cases took dl-3-butylphthalide and the counterpart of 47 cases took no other treatment. The dl-3-butylphthalide therapy requires 200mg each time, and 3 times a day. Results： Significant difference was shown in the assessment in the 11th day and 21st day of NIHSS （ National Institutes of Health Stroke Survey ） and ADL （Barthel Activities of Daily Living Index） between the two groups. No significant difference was shown in the laboratory data of the therapeutic group before and after the treatment. Conclusion： dl-3-butylphthalide makes constructive contribution to the clinical treatment of acute cerebral infarction. Since it is of no significant reaction on liver and renal function, plasma fat, plasma glucose and EKG, it should be regarded as an effective and safety treatment.
出处
《中国临床神经科学》
2006年第3期281-284,共4页
Chinese Journal of Clinical Neurosciences
